GlassScriptPhysician profile
Benjamin Jewett
NPI 1184283889
$6,862.93
in general payments reported to CMS, 2019-2025
32 companies · $5,543 in 2025
The $5,543 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,320 · 2025: $5,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239 · Consulting Fee: $1,600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,239.08 |
| Consulting Fee | $1,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,789.67 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Ucb, INC. | $1,045.06 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $617.86 | 2024-2025 | |
| Pfizer INC. | $387.05 | 2024-2025 | |
| Neurelis, INC. | $341.76 | 2024-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $337.10 | 2024-2025 | |
| Tg Therapeutics, INC. | $277.43 | 2025 | |
| Lundbeck LLC | $251.17 | 2024-2025 | Vyepti |
| Argenx US, INC. | $225.32 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $196.08 | 2024-2025 | Apokyn, Xadago |
| Eisai INC. | $175.47 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $124.93 | 2025 | |
| Grifols USA, LLC | $113.65 | 2025 | Gamunex-C |
| Novartis Pharmaceuticals Corporation | $108.09 | 2024-2025 | |
| Emd Serono, INC. | $106.83 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $84.31 | 2024 | Ultomiris |
| Livanova USA, INC. | $81.81 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Vanda Pharmaceuticals INC. | $74.12 | 2025 | Ponvory |
| Celgene Corporation | $68.98 | 2025 | Zeposia |
| Csl Behring | $63.15 | 2025 | Hizentra |
| Scilex Pharmaceuticals INC. | $59.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $41.01 | 2025 | Wainua |
| Ipsen Biopharmaceuticals, INC | $39.58 | 2024 | Dysport |
| Catalyst Pharmaceuticals, INC. | $38.71 | 2025 | |
| Axsome Therapeutics, INC. | $36.14 | 2025 | Symbravo |
| Medtronic, INC. | $28.30 | 2025 | Intellis Adaptivestim |
| Ge Healthcare | $28.13 | 2025 | |
| Amneal Pharmaceuticals LLC | $27.68 | 2025 | Crexont |
| Genzyme Corporation | $25.51 | 2025 | |
| Genentech USA, INC. | $23.77 | 2025 | Ocrevus Zunovo |
| Sanara Medtech INC. | $23.50 | 2024 | Celleraterx |
| Merz Pharmaceuticals, LLC | $21.05 | 2025 | Xeomin, Ampyra, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Jewett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.